Detalhe da pesquisa
1.
A Phase 1 Study To Evaluate Safety and Pharmacokinetics following Administration of Single and Multiple Doses of the Antistaphylococcal Lysin LSVT-1701 in Healthy Adult Subjects.
Antimicrob Agents Chemother
; 66(3): e0184221, 2022 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35007129
2.
Efficacy of Antistaphylococcal Lysin LSVT-1701 in Combination with Daptomycin in Experimental Left-Sided Infective Endocarditis Due to Methicillin-Resistant Staphylococcus aureus.
Antimicrob Agents Chemother
; 65(8): e0050821, 2021 07 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-34097491
3.
Effect of Vancomycin-Associated Acute Kidney Injury on Incidence of 30-Day Readmissions among Hospitalized Veterans Affairs Patients with Skin and Skin Structure Infections.
Antimicrob Agents Chemother
; 64(10)2020 09 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-32718970
4.
In Vitro Activity of Iclaprim against Isolates in Two Phase 3 Clinical Trials (REVIVE-1 and -2) for Acute Bacterial Skin and Skin Structure Infections.
Antimicrob Agents Chemother
; 63(4)2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30642922
5.
In Vitro Activities of ß-Lactam-ß-Lactamase Inhibitor Antimicrobial Agents against Cystic Fibrosis Respiratory Pathogens.
Antimicrob Agents Chemother
; 64(1)2019 12 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-31611364
6.
Iclaprim activity against wild-type and corresponding thymidine kinase-deficient Staphylococcus aureus in a mouse protection model.
Eur J Clin Microbiol Infect Dis
; 38(2): 409-412, 2019 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-30483998
7.
A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Vs Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed to be Due to Gram-Positive Pathogens: REVIVE-1.
Clin Infect Dis
; 66(8): 1222-1229, 2018 04 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29281036
8.
Identification of the In Vivo Pharmacokinetics and Pharmacodynamic Driver of Iclaprim.
Antimicrob Agents Chemother
; 62(4)2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29378717
9.
Pharmacokinetic and Pharmacodynamic Analyses To Determine the Optimal Fixed Dosing Regimen of Iclaprim for Treatment of Patients with Serious Infections Caused by Gram-Positive Pathogens.
Antimicrob Agents Chemother
; 62(2)2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29133566
10.
A Phase 3, Randomized, Double-Blind, Multicenter Study To Evaluate the Safety and Efficacy of Intravenous Iclaprim versus Vancomycin for Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed To Be Due to Gram-Positive Pathogens (REVIVE-2 Study).
Antimicrob Agents Chemother
; 62(5)2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29530858
11.
Efficacy evaluation of iclaprim in a neutropenic rat lung infection model with methicillin-resistant Staphylococcus aureus entrapped in alginate microspheres.
Eur J Clin Microbiol Infect Dis
; 37(4): 673-678, 2018 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-29222698
12.
In Vitro Activity of Iclaprim against Methicillin-Resistant Staphylococcus aureus Nonsusceptible to Daptomycin, Linezolid, or Vancomycin: A Pilot Study.
Can J Infect Dis Med Microbiol
; 2017: 3948626, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-29527229
13.
Combination therapy with lysin CF-301 and antibiotic is superior to antibiotic alone for treating methicillin-resistant Staphylococcus aureus-induced murine bacteremia.
J Infect Dis
; 209(9): 1469-78, 2014 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24286983
14.
Plasmid transferability of KPC into a virulent K2 serotype Klebsiella pneumoniae.
BMC Infect Dis
; 14: 176, 2014 Mar 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-24678611
15.
A risk score for identifying methicillin-resistant Staphylococcus aureus in patients presenting to the hospital with pneumonia.
BMC Infect Dis
; 13: 268, 2013 Jun 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-23742753
16.
Comparison of serotonin toxicity with concomitant use of either linezolid or comparators and serotonergic agents: an analysis of Phase III and IV randomized clinical trial data.
J Antimicrob Chemother
; 67(2): 494-502, 2012 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-22139199
17.
Linezolid effects on bacterial toxin production and host immune response: review of the evidence.
Curr Ther Res Clin Exp
; 73(3): 86-102, 2012 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24648596
18.
Engineered peptide PLG0206 overcomes limitations of a challenging antimicrobial drug class.
PLoS One
; 17(9): e0274815, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36112657
19.
The activity of the diaminopyrimidine dihydrofolate reducatase inhibitor, iclaprim, against Toxoplasma gondii in an in vitro model: a pilot study.
Diagn Microbiol Infect Dis
; 99(4): 115296, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33387894
20.
Anti-staphylococcal lysin, LSVT-1701, activity: In vitro susceptibility of Staphylococcus aureus and coagulase-negative staphylococci (CoNS) clinical isolates from around the world collected from 2002 to 2019.
Diagn Microbiol Infect Dis
; 101(3): 115471, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-34280671